BUSINESS

• Medipal/JCR’s MPS IIIB Therapy Earns Orphan Status in Europe
  June 25, 2025

• Aculys Moves Toward First Launch as It Tackles Japan’s Drug Lag/Loss
  June 24, 2025

• Axcelead, Superluminal Pair Up to Target Challenging Molecular Mechanisms
  June 24, 2025

• Otsuka Bags Rights to Bispecific T-Cell Engager from China’s Harbour
  June 24, 2025

• Ono Snags Japan, Korea Rights to Vertex’s Povetacicept
  June 24, 2025

• GMP Deviation at CMO Katsuyama Caused Viatris Shipment Halt
  June 23, 2025

• Boehringer to Invest 300 Million Euros in New Facilities at Yamagata Plant
  June 23, 2025

• GSK’s RSV Vaccine Arexvy Filed for High-Risk Adults Aged 18-49 in Japan
  June 23, 2025

• Moderna Files Next-Gen COVID Vaccine in Japan
  June 23, 2025

• SanBio, Minaris Aim to Expand Global Reach of Akuugo
  June 20, 2025

• Japan Rare Disease Drug Market to Grow Nearly 70% by 2040: Fuji Keizai
  June 20, 2025

• Viatris Pauses Shipments of Polyful, Other Drugs over Manufacturing Issues
  June 20, 2025

• Vietnam Clears Epadel for Import, Launch Planned via Partner: Mochida/Meiji
  June 20, 2025

• Shionogi Clinches Tender Offer for Torii, Sets Stage for Full Takeover by September
  June 20, 2025

• NEC Reports Positive Results in AI Demo for Predicting Cancer Drug Combos
  June 19, 2025

• Axcelead, Lotte, Kanaph Join Forces to Push ADCs
  June 19, 2025

• Will Moderna See Multiple Japan Filings in the Coming Years? 5 Late-Stage Assets in Pipeline
  June 19, 2025

• Taking on Solid Tumors - 6: Pfizer Japan Sees Rosy Uptake with Elrexfio, Mulling Bringing Bispecific Assets for Solid Cancers Too
  June 18, 2025

• Otsuka’s Therapeutic App for Depression Now Available in Great Britain
  June 18, 2025

• Alfresa Teams Up with HekaBio, Swanielle to Fight Drug Lag/Loss
  June 18, 2025

ページ

• « 先頭
• ‹ Prev
• …
• 46
• 47
• 48
• 49
• 50
• 51
• 52
• 53
• 54
• …
• Next ›
• 最終 »